Evidence map›Paper›PMID 29387000›Full record

ArticleFrontiers in cellular neuroscience2018

Intermittent Fasting Applied in Combination with Rotenone Treatment Exacerbates Dopamine Neurons Degeneration in Mice.

Giuseppe Tatulli, Nico Mitro, Stefano M Cannata, Matteo Audano, Donatella Caruso, Giovanna D'Arcangelo, Daniele Lettieri-Barbato, Katia Aquilano

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cellular neuroscience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Giuseppe TatulliIRCCS San Raffaele La Pisana, Rome, Italy.
Nico MitroDepartment of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy.
Stefano M CannataDepartment of Biology, University of Rome Tor Vergata, Rome, Italy.
Matteo AudanoDepartment of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy.
Donatella CarusoDepartment of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy.
Giovanna D'ArcangeloDepartment of Medical Systems, University of Rome Tor Vergata, Rome, Italy.
Daniele Lettieri-BarbatoIRCCS San Raffaele La Pisana, Rome, Italy.
Katia AquilanoIRCCS San Raffaele La Pisana, Rome, Italy.
University of Milan · ITUniversity of Rome Tor Vergata · ITIstituto di Ricovero e Cura a Carattere Scientifico San Raffaele

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intermittent fasting (IF) was suggested to be a powerful nutritional strategy to prevent the onset of age-related neurodegenerative diseases associated with compromised brain bioenergetics. Whether the application of IF in combination with a mitochondrial insult could buffer the neurodegenerative process has never been explored yet. Herein, we defined the effects of IF in C57BL/6J mice treated once per 24 h with rotenone (Rot) for 28 days. Rot is a neurotoxin that inhibits the mitochondrial complex I and causes dopamine neurons degeneration, thus reproducing the neurodegenerative process observed in Parkinson's disease (PD). IF (24 h alternate-day fasting) was applied alone or in concomitance with Rot treatment (Rot/IF). IF and Rot/IF groups showed the same degree of weight loss when compared to control and Rot groups. An accelerating rotarod test revealed that only Rot/IF mice have a decreased ability to sustain the test at the higher speeds. Rot/IF group showed a more marked decrease of dopaminergic neurons and increase in alpha-synuclein (α-syn) accumulation with respect to Rot group in the

Indexed as

excitatory amino acidslysophospholipidsmitochondriaParkinson’s disease

Identifiers

PMID29387000
PMCPMC5776087
OpenAlexW2783527941

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.